Liver Cancer
Copyright ©The Author(s) 2004.
World J Gastroenterol. Aug 1, 2004; 10(15): 2195-2200
Published online Aug 1, 2004. doi: 10.3748/wjg.v10.i15.2195
Figure 4
Figure 4 Hepatoma angiogenesis inhibited by gene therapy of endostatin and IL-12. MVD (CD31staining, 200 × ) of hepatoma treated with pSecES/PVP (7.3 ± 1.2) (B), pmIL-12/PVP (10.0 ± 1.7) (C) or pSecES + pmIL-12/PVP (3.7 ± 1.2) (D) was less than that treated with pcDNA3.1/PVP (22.7 ± 3.1, P < 0.05) (A).